The optimal indication for FiLaC® is high trans-sphincteric fistula-in-ano: a prospective cohort of 69 consecutive patients

Marref, I; Spindler, Louise; Aubert, M; Lemarchand, Nicolas; Fathallah, Nadia; Pommaret, Elise; Soudan, D.; Moult, Hélène Pillant-Le; Far, E Safa; Fellous, K; Crochet, Élise; Mory, Ben; Benfredj, Paul; Parades, Vincent de

doi:10.1007/s10151-019-02077-9

Cited by 29 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По мнению большинства авторов, ревизия, кюретаж и установка дренирующего сетона как 1-го этапа лечения за 12 нед до лазерной аблации помогают в формировании фиброзной ткани и созревании свищевого хода [6,7,[27][28][29]. Двухэтапная методика позволяет сформировать свищевой ход оптимального диаметра (4 мм), что дает возможность наиболее эффективно использовать лазерную технологию для лечения.…”

Section: состояние проблемыunclassified

Evolution of treatment for rectal fistula: from resection to FiLaC® laser ablation

Атрощенко

Kiselev

Pozdnyakov

et al. 2021

Onkol. koloproktol.

View full text Add to dashboard Cite

Rectal fistula – one of the most common coloproctological diseases. Annually, thousands of patients with anal fistula have had treated around the world. Treatment of this disease is an actual problem in coloproctology nowadays due to the high frequency of recurrence and anal incontinency. The chronic persistent perianal suppuration and multiple surgical interventions the main predictor of emergence of the anal incontinence, which could be achieve almost 50 %, according the literature data. The risk of emergence the anal incontinence is particularly high in the treatment of complex fistulas. Therefore, the problem of complex rectal fistulas treating remains an actual task in the clinical practice of a coloproctologist.

show abstract

Section: состояние проблемыunclassified

Evolution of treatment for rectal fistula: from resection to FiLaC® laser ablation

Атрощенко

Kiselev

Pozdnyakov

et al. 2021

Onkol. koloproktol.

View full text Add to dashboard Cite

show abstract

“…2014; Giamundo [24] 2014; Öztürk [27] 2015; Giamundo [23] 2017; Wilhelm [29] 2017; Dönmez [22] 2018; Lauretta [25] 2018; Terzi [28] 2019; Marref [26] 0,2 0,4 0 2014; Giamundo [24] 2014; Öztürk [27] 2015; Giamundo [23] 2017; Wilhelm [29] 2018; Lauretta [25] 2019; Marref [26] 0,0 0,1 0,2 0,3 Proportion 0,4 0,5…”

Section: Sucess Rate (A) (B)mentioning

confidence: 99%

“…In the first study by Giamundo et al [24] in 2014, the laser energy was 13 W with 980 nm wavelength in eight patients, whereas in the remaining 27 patients the laser energy was 10 W with 1470 nm wavelength. Marref et al [26] utilized a laser energy of 12-15 W with 1470 nm wavelength ( Table 2).…”

Section: Technical Aspectsmentioning

confidence: 99%

“…Two studies were excluded20,21 and eight studies were included in our meta-analysis (Table 1), which included 476 patients who underwent the FiLaC TM procedure for the treatment of perianal fistula [22][23][24][25][26][27][28][29]. Among these patients 63% experienced a successful closure after FiLaC TM and 8% had a postoperative complication.…”

Section: Included Studiesmentioning

confidence: 99%

“…2014; Giamundo [24] 2014; Öztürk [27] 2015; Giamundo [23] 2017; Wilhelm [29] 2017; Dönmez [22] 2018; Lauretta [25] 2018; Terzi [28] 2019; Marref [26] 0,2 0,4 0,6 0,8 63% (95% CI = 50 -75) 8% (95% CI = 1 -18)…”

Section: Sucess Rate (A) (B)mentioning

confidence: 99%

See 2 more Smart Citations

Could FiLaC™ be effective in the treatment of anal fistulas? A systematic review of observational studies and proportional meta‐analysis

et al. 2020

View full text Add to dashboard Cite

Aim Fistula Laser Closure (FiLaC TM) is a novel sphincter-preserving technique that is based on new technologies and shows promising results in repairing anal fistulas whilst maintaining external sphincter function. The aim of the present meta-analysis is to present the efficacy and the safety of FiLaC TM in the management of anal fistula disease. Method The present proportional meta-analysis was designed using the PRISMA and AMSTAR guidelines. We searched MEDLINE, Scopus, clinicaltrials.gov, Embase, Cochrane Central Register of Controlled Trials CENTRAL and Google Scholar databases from inception until November 2019. Results Overall, eight studies were included that recruited 476 patients. The pooled success rate of the technique was 63% (95% CI 50%-75%). The pooled complication rate was 8% (95% CI 1%-18%). Sixty-six per cent of patients had a transsphincteric fistula and 60% had undergone a previous surgical intervention, mainly the insertion of a seton (54%). The majority had a cryptoglandular fistula. Operation time and follow-up period were described for each study. Conclusion FiLaC TM seems to be an efficient therapeutic option for perianal fistula disease with an adequate level of safety that preserves quality of life. Nevertheless, randomized trials need to be designed to compare FiLaC TM with other procedures for the management of anal fistulas such as ligation of intersphincteric fistula tract, anal advancement flaps, fibrin glue, collagen paste, autologous adipose tissue, fistula plug and video-assisted anal fistula treatment.

show abstract

Optimal Management of the Transsphincteric Anal Fistula

Rahman,

Tsikitis

2023

Difficult Decisions in Colorectal Surgery

View full text Add to dashboard Cite

The optimal indication for FiLaC® is high trans-sphincteric fistula-in-ano: a prospective cohort of 69 consecutive patients

Cited by 29 publications

References 18 publications

Evolution of treatment for rectal fistula: from resection to FiLaC® laser ablation

Evolution of treatment for rectal fistula: from resection to FiLaC® laser ablation

Could FiLaC™ be effective in the treatment of anal fistulas? A systematic review of observational studies and proportional meta‐analysis

Optimal Management of the Transsphincteric Anal Fistula

Contact Info

Product

Resources

About